Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer

C.J. WATSON1*, H. O’KANE1*, P. MAXWELL2, O. SHARAF3, I. PETAK4, P.L. HYLAND1, D. O’ROUKE5, J. McKNIGHT1, P. CANNING6 and K. WILLIAMSON3

1Centre for Cancer Research and Cell Biology, Queens University Belfast; 2Tissue Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK; 3St. Vincent’s University Hospital and Conway Institute University College Dublin, Dublin, Ireland; 4Department of Medical Chemistry, Molecular Biology and Pathobiology, Semmelweis University, Budapest, Hungary; 5Department of Pathology, Belfast City Hospital; 6Centre for Infection and Immunity, Queen’s University Belfast, Belfast, Northern Ireland, UK

Received August 31, 2011; Accepted October 7, 2011

DOI: 10.3892/ijo.2011.1250

Abstract. We characterized Fas immunoreactivity, functionality and its role in the response to mitomycin-C (MMC) chemotherapy in vitro in cell lines and in vivo in bladder washings from 23 transitional cell carcinoma of the bladder (TCCB) patients, harvested prior to and during MMC intravesical treatment. Having established the importance of functional Fas, we investigated the methylation and exon 9 mutation as mechanisms of Fas silencing in TCCB. For the first time, we report p53 up-regulation in 9/14 and Fas in 7/9 TCCB patients during intravesical MMC treatment. Fas immunoreactivity was strong in the TCCB cell line T24 and in 17/20 (85%) tumor samples from patients with advanced TCCB. T24 and HT1376 cells were resistant to MMC and recombinant Fas ligand, whilst RT4 cells were responsive to Fas ligand and MMC. Using RT4 cells as a model, siRNA targeting p53 significantly reduced MMC-induced p53 and Fas up-regulation and stable DN-FADD transfection decreased MMC-induced apoptosis, suggesting that functional Fas enhances chemotherapy responses in a p53-dependent manner. In HT1376 cells, 5-aza-2-deoxycytidine (12 µM) induced Fas immunoreactivity and reversed methylation at CpG site -548 within the Fas promoter. This site was methylated in 13/24 (54%) TCCB patient samples assessed using Methylation-Specific Polymerase Chain Reaction. There was no methylation at either the p53 enhancer region within the first intron or at the SP-1 binding region in the promoter and no mutation within exon 9 in tumor DNA extracted from 38 patients. Methylation at CpG site -548 is a potential target for demethylating drugs.

Introduction

Activation of the death receptor Fas pathway can occur through binding with Fas ligand (Fas-L), which is expressed on cytotoxic immune cells, namely natural killer cells and activated T lymphocytes (1,2). This pathway facilitates the elimination of unwanted cells and therefore provides an important means of tumor immune surveillance. Loss of Fas protein has been implicated in tumorigenesis (3-5); reduced Fas expression has been associated with higher stage and grade bladder tumors (6,7) and introduction of Fas cDNA has been considered as a therapeutic option (8).

Ablation of Fas protein expression could be attributable to mutations or epigenetic silencing (9,10). During carcinogenesis, cancer cells acquire alterations in methylation patterns (11). DNA methylation occurs through the enzymatic addition of a methyl group to the carbon five prime position of a cytosine pyrimidine ring of DNA and is almost exclusively restricted to CpG dinucleotides. Hypermethylation increases with aging, is associated with gene silencing and constitutes a stable mark that is maintained through continuous rounds of cell division. Generally in cancer, there is hypomethylation in intergenic regions of the genome and hypermethylation within promoter regions, particularly of tumor suppressor genes and this leads to epigenetic silencing (12). For example, CDKN2A, CDHI (E-cadherin) and SYCG are silenced through hypermethylation in urothelial cancers (13-16). Some studies have recently appraised the methylation status of panels of genes in TCCB (11,17). The promoter region of Fas is GC rich and contains a relatively high number of CpG dinucleotides, as does the p53 responsive element within its first intron. These areas are potential targets for DNA methylation (18). DNA methylation of the Fas gene has been demonstrated in colorectal cancer (19). However, although Lee et al have reported missense mutations within exon 9, which may affect the critical death
Materials and methods

Patients and tissues. Two studies were approved by the Research Ethics Committees, Queen's University Belfast (334/00) and ORECN1 (392/02) and hospital review boards. Written consent was obtained from each patient. Patients, naïve to any treatment, were recruited prior to transurethral resection of bladder tumor (TURBT) from two Belfast hospitals between January 2001 and April 2005 (Fig. 1). All patient notes were reviewed to determine which tumors recurred or progressed.

Fifteen patients were recruited to Study 1 to study p53 up-regulation post-MMC treatment in bladder washings. Fifty patients were recruited to Study 2; 34 for analyses of tumor samples only and 16 for analyses of both dynamic up-regulation of Fas in bladder washings and immunohistochemical and molecular analyses of their corresponding tumor samples.

Assessment of the levels of p53 and Fas protein in vivo in tumor cells after MMC treatment. The 15 patients recruited to Study 1 were admitted on three occasions, one week apart, and received intravesical 40 mg/40 ml MMC (Kyowa Hakko, Ltd., UK) for 1 h, prior to transurethral resection of bladder tumor (TURBT), as described by Maffezzini et al (21). On each admission, patients had bladder washings prior to and at 1.5, 4.0 and 6.0 h post-MMC. To study the dynamics of Fas expression, 16 patients recruited to Study 2 received MMC prior to TURBT in a manner similar to that described for p53 in Study 1. Samples from the first four patients were used to optimise protocols for Fas immunostaining. The assessment timings were prior to and 2.0, 4.0, 6.0 and 24.0 h after MMC treatment to accommodate the immediate immunostaining which was required for Fas detection on unfixed cells.

In both Study 1 and 2, immunocytochemistry was performed on tumor cells retrieved from bladder washings prior to and after MMC chemotherapy. Unfixed (Fas) or methanol fixed (p53) cells were incubated for 1 h at RT with 1.5 µg/ml Fas conjugated to R-phycocerythrin (RPE) (DX2-RPE) or 8.0 µg/ml anti-p53 (DO7), respectively. Matching IgG antibodies at equivalent concentrations were run as controls. p53 antibody binding was visualized using RPE (Dako). Nuclear p53 and cytoplasmic Fas were confirmed using a confocal Leica SP2 microscope prior to analysis on a Coulter Epics Elite ESP flow cytometer. Seven thousand five hundred events, gated to exclude debris and doublets, were analysed for each sample. Isotype controls were analysed immediately prior to their corresponding test samples which were both run at the same voltage. Overlay histograms representing Fas or p53 protein expression levels at each time-point were appraised by two independent observers. Patients were classified as dynamic up-regulators if the p53 or Fas levels increased above the pre-treatment levels at any post-treatment time-point.

Assessment of tumor cells retrieved from sequential bladder washings. An aliquot of cells retrieved from each bladder wash was fixed immediately in cytospin collection fluid (Shandon, Browne, Ltd., Mallusk, Northern Ireland) and Papanicolaou stained using the Shandon Varistain 24.3 prior to assessment by a pathologist.

Fas and p53 immunohistochemistry on tumor samples. Tissue sections (3 µm) cut from TURBT samples from 49/50 patients recruited to Study 2 were treated with 0.01 M citrate buffer at pH 6.0 for 22 min in a microwave oven at 750 W before incubation with 3 µg/ml anti-Fas, 5 µg/ml anti-p53 or isotype controls. One patient with squamous cell carcinoma of the bladder was excluded. Immunoreactivity was detected using EnVision (Dako). Two independent observers classified tumors as Fas positive when >10% of tumor cells had cytoplasmic or membranous positivity and p53 positive when >10% of tumor cells had nuclear positivity.

Cell culture and in vitro treatments. Three human bladder carcinoma cell lines; HT1376, RT4 and T24, together with the colorectal cell line Caco2, were obtained from the Collection of Cell Culture (Salisbury, UK). HT1376 cells were maintained in Eagle's modified essential medium (EMEM) (Sigma-Aldrich, Dorset, UK); RT4 and T24 in McCoy's 5A medium (Sigma-Aldrich); and Caco2 in RPMI-medium (Sigma-Aldrich) at 37°C in a 5% carbon dioxide atmosphere.

This study highlights the importance of Fas functionality in the response to mitomycin-c (MMC) induced apoptosis and then tests the hypothesis that methylation within the Fas promoter silences Fas expression in TCCB cells. We identified CpG methylation site at position -548 of the Fas promoter, which was present in 13/24 (54%) of TCCB tumors investigated.

CpG methylation at position -548 of the Fas gene in transitional cell carcinoma of the bladder (TCCB). The 15 patients recruited to Study 1 were admitted on three occasions, one week apart, and received intravesical 40 mg/40 ml MMC (Kyowa Hakko, Ltd., UK) for 1 h, prior to transurethral resection of bladder tumor (TURBT), as described by Maffezzini et al (21). On each admission, patients had bladder washings prior to and at 1.5, 4.0 and 6.0 h post-MMC. To study the dynamics of Fas expression, 16 patients recruited to Study 2 received MMC prior to TURBT in a manner similar to that described for p53 in Study 1. Samples from the first four patients were used to optimise protocols for Fas immunostaining. The assessment timings were prior to and 2.0, 4.0, 6.0 and 24.0 h after MMC treatment to accommodate the immediate immunostaining which was required for Fas detection on unfixed cells.

In both Study 1 and 2, immunocytochemistry was performed on tumor cells retrieved from bladder washings prior to and after MMC chemotherapy. Unfixed (Fas) or methanol fixed (p53) cells were incubated for 1 h at RT with 1.5 µg/ml Fas conjugated to R-phycocerythrin (RPE) (DX2-RPE) or 8.0 µg/ml anti-p53 (DO7), respectively. Matching IgG antibodies at equivalent concentrations were run as controls. p53 antibody binding was visualized using RPE (Dako). Nuclear p53 and cytoplasmic Fas were confirmed using a confocal Leica SP2 microscope prior to analysis on a Coulter Epics Elite ESP flow cytometer. Seven thousand five hundred events, gated to exclude debris and doublets, were analysed for each sample. Isotype controls were analysed immediately prior to their corresponding test samples which were both run at the same voltage. Overlay histograms representing Fas or p53 protein expression levels at each time-point were appraised by two independent observers. Patients were classified as dynamic up-regulators if the p53 or Fas levels increased above the pre-treatment levels at any post-treatment time-point.

Assessment of tumor cells retrieved from sequential bladder washings. An aliquot of cells retrieved from each bladder wash was fixed immediately in cytospin collection fluid (Shandon, Browne, Ltd., Mallusk, Northern Ireland) and Papanicolaou stained using the Shandon Varistain 24.3 prior to assessment by a pathologist.

Fas and p53 immunohistochemistry on tumor samples. Tissue sections (3 µm) cut from TURBT samples from 49/50 patients recruited to Study 2 were treated with 0.01 M citrate buffer at pH 6.0 for 22 min in a microwave oven at 750 W before incubation with 3 µg/ml anti-Fas, 5 µg/ml anti-p53 or isotype controls. One patient with squamous cell carcinoma of the bladder was excluded. Immunoreactivity was detected using EnVision (Dako). Two independent observers classified tumors as Fas positive when >10% of tumor cells had cytoplasmic or membranous positivity and p53 positive when >10% of tumor cells had nuclear positivity.

Cell culture and in vitro treatments. Three human bladder carcinoma cell lines; HT1376, RT4 and T24, together with the colorectal cell line Caco2, were obtained from the Collection of Cell Culture (Salisbury, UK). HT1376 cells were maintained in Eagle's modified essential medium (EMEM) (Sigma-Aldrich, Dorset, UK); RT4 and T24 in McCoy's 5A medium (Sigma-Aldrich); and Caco2 in RPMI-medium (Sigma-Aldrich) at 37°C in a 5% carbon dioxide atmosphere.
Media were supplemented with 10% FCS, 4 mM L-glutamine, 0.06 mg/ml benzylpenicillin and 0.1 mg/ml streptomycin.

In separate experiments, cells were incubated with i) 100 ng/ml Fas-L (Calbiochem, Nottingham, UK) for 16 h, ii) MMC (0-500 µg/ml) for 1 h or iii) with either 1 or 12 µM 5-aza-2'-deoxycytidine (5azaDC) (Sigma-Aldrich) for 72 h to assess functionality of the Fas pathway, MMC chemosensitivity and the effects of global methylation, respectively.

**Immunocytochemistry on cell lines.** Immunocytochemistry on treated and untreated cell lines prior to and after treatments was performed as described. Unfixed (Fas), methanol fixed (p53) or cells fixed in Carnoy's and acid denatured with 1 M HCl at 60°C for 10 min (5MeC), were incubated for 1 h at RT with 5.0 µg/ml anti-Fas (DX2), 8.0 µg/ml anti-p53 (DO7) or 2 µg/ml anti-5-methylcytidine (anti-5MeC) antibodies, respectively. IgG1 or IgG2b antibodies were used at equivalent concentrations as controls. Antibody binding was visualized using EnVision, fluorescein isothiocyanate isomer 1 (FITC) secondary antibody or RPE (Dako) prior to analysis on a Coulter Epics Elite ESP flow cytometer as described for the harvested tumor cells. Data were stored as listmode files and subsequently analysed using Immuno-4 software (Beckman Coulter) which generated the percentage of positively staining cells (%) and the intensity of immunofluorescence (MCF).

Western blotting on cell lines. Fas and p53 were extracted from cells grown in culture using the ProteoExtract® Native Membrane Protein Extraction kit (Calbiochem) and the NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology), respectively, according to manufacturer's instructions. Ten micrograms of membrane or nuclear protein were denatured, reduced and resolved on 4-12% gels (Invitrogen) by SDS-PAGE before transfer onto 0.2-µm pore size nitrocellulose membrane (Invitrogen). Membranes treated with blocking buffer (3% BSA in TBST) for 2 h were probed overnight with either rabbit anti-human Fas polyclonal antibody (antiserum C20) from Santa Cruz Biotechnology Inc., Heidelberg, Germany diluted 1:200 or human Fas polyclonal antibody (antiserum C20) from Santa Cruz Biotechnology Inc., Heidelberg, Germany diluted 1:200 or 2.0 µg/ml anti-p53 (Dako).

**Flow cytometry assessment of cell cycle and sub G0/G1 events in cell lines.** For assessment of apoptosis, alcohol-fixed cells, both treated and untreated, were washed in PBS before staining with propidium iodide. At least 10,000 events, gated using peak versus integral fluorescence to eliminate doublets and clumps, were collected through a 610-nm long pass filter. DNA histograms were evaluated and events falling within a sub-G0/G1 gate were enumerated.

**p53 siRNA transfection in RT4 cells.** RT4 cells were incubated with 100 nM p53 siRNA (Dharmacon, UK), control siRNA (Dharmacon) or transfectant only according to manufacturer's instructions. Untransfected cells were included as additional controls. Cells were cultured in fresh growth medium for a further 24 h before treatment with 50 µg/ml MMC or control media for 1 h. To inhibit p53 induction following MMC treatment, cells were re-transfected with p53 siRNA or control siRNA and cultured for a further 24 h. Levels of p53 and Fas and the number of sub G0/G1 events were assessed using flow cytometry, as described.

**FADD-DN transfection to inhibit the Fas apoptotic pathway in RT4 cells.** RT4 cells were transfected with a FADD-DN construct [cDNA corresponding to amino acids 80-208 of FADD together with an N-term AU1 epitope tag (22) or empty vector by electroporation using a Nucleofector® Device (Amazx Biosystems, Cologne, Germany)]. Transfected cells were selected using 500 µg/ml G418 (BD Biosciences, Oxford, UK) over 3 months. Stable integration and expression of the AU1-tagged FADD-DN was confirmed by immunocytochemical detection using 5 µg/ml of anti-AU1 antibody (Abcam). DN-FADD and vector transfected cells growing on coverslips were treated for 1 h with 10 µg/ml MMC or control media followed by incubation in MMC-free media for 24 h. An observer, blinded to the treatments, determined the number of apoptotic cells in 20 high power fields (HPF) on Giemsa stained preparations.

**Bisulfite genomic sequencing of the Fas promoter region in cell lines.** We determined the effects of 5azaDC treatment on Fas immunoreactivity in HT1376, RT4 and T24 cells prior to Bisulfite Genomic Sequencing (BGS). We bisulfite treated extracted DNA from the three cell lines prior to using published primers (19) (Table I) to amplify a 583-bp region of the Fas promoter (-575 to +8) which contains 28 CpG dinucleotides.

The amplified Fas promoter fragment was ligated into the pcR2.1TOPO vector and transformed into TOP10 competent E. coli using the TOPO TA Cloning kit (Invitrogen). Multiple clones were analyzed using EcoRI restriction endonuclease digestion (RE) and agarose gel electrophoresis to confirm insertion of the Fas promoter fragment. Two independent positive PCR and RE clones from each sample were subjected to direct sequencing using the BigDye® Terminator v1.1 Cycle Sequencing kit (ABI) and the ABI PRISM™ 310 Genetic Analyser according to manufacturer's instruction. Data were analysed using SeqMan II software (DNASTar) to produce a consensus sequence from each clone.

**Methylation-specific PCR on tumor samples and cell lines.** Methylation specific PCR (MSPCR) was carried out on extracted tumor DNA from the TCCB patients recruited to Study 2. Total genomic DNA was successfully extracted from 5-µm sections from representative tumor blocks from 38 patients and three cell lines using the Ex-Wax DNA Extraction kit (Intergen) or the DNeasy™ Tissue kit (Qiagen), respectively, according to manufacturer's instructions. MSPCR primers were used to determine the methylation status of i) the potential methylation hotspot at CpG site -548 within the Fas promoter in 24 patients, ii) the p53 enhancer region within the first intron of the Fas gene (19) in 38 patients and iii) the Sp1 binding region within the Fas promoter (-575 to +8) which contains 28 CpG dinucleotides.

We determined the effects of 5azaDC treatment on Fas immunoreactivity in HT1376, RT4 and T24 cells prior to Bisulfite Genomic Sequencing (BGS). We bisulfite treated extracted DNA from the three cell lines prior to using published primers (19) (Table I) to amplify a 583-bp region of the Fas promoter (-575 to +8) which contains 28 CpG dinucleotides.
PCR amplification and exon 9 sequencing of DNA extracted from 38 TCCB patients. Mutations within exon 9 which encodes the death domain of Fas have been linked with bladder cancer (20). We examined three specific mutations in this region using previously described primers (20) and direct DNA sequence analysis in DNA extracted from 38 patients. Each of the exon 9 PCR products were gel purified electrophoresed on a 2% ethidium bromide stained agarose gel to detect product which was purified using Wizard® PCR Preps DNA purification system (Promega) and subjected to direct DNA sequence analysis according to manufacturer's instructions. Data were analysed using SeqMan II software (DNAStar) to produce a consensus sequence for each amplified exon 9 product.

Statistics. Statistical comparisons were performed using SPSS for Windows Version 17. Pearson's $\chi^2$ and t-test were used to identify significant associations and differences, respectively. The significance level was $p<0.05$.

Results

Intravesical MMC treatment increased Fas and p53 expression in vivo in tumor cells from some patients. Bladder washings from 31 TCCB patients were analysed to determine whether p53 and/or Fas protein expression was up-regulated in response to MMC (Fig. 1). Cytological assessment confirmed that bladder washings contained normal urothelial and tumor cells; some of which were undergoing apoptosis (Fig. 2A). Dynamic p53 up-regulation in tumor cells after intravesical MMC was assessed in 10 pTa, three pT1 and one unresectable tumor from 13 males and one female (mean age 67.5 years) (mean follow-up, 5 months). One patient withdrew from the study. Nine of the 14 (64%) patients shed tumor cells which dynamically up-regulated p53 following MMC treatment. There was no evidence of p53 up-regulation in cells obtained from the patient with an unresectable tumor who later died from a lung metastasis. Dynamic Fas up-regulation in tumor cells was assessed in two pTaG1, six pTaG2, one pTaG3, six pT1G3 and one pT2G3 from 15 males and one female (mean age, 67.0 years) (mean follow-up, 13.5 months). The first four patients were used to establish the Fas immunostaining. Unfortunately, control samples in three patients failed. Seven of the nine remaining patients up-regulated Fas following intravesical MMC; two were recurrence-free, four had recurrences and one had pTaG2 disease (there was no follow-up for this patient). One patient who progressed and one with pT2G3 disease had static Fas immunoreactivity (Fig. 2B).

Positive Fas immunoreactivity (IHC) is associated with advanced disease. One tumor was a squamous cell carcinoma and was excluded from the study. Twenty-five pTa, 16 pT1, seven pT2 and one pT3 tumor were collected from 45 males and three females (mean follow-up,14.2 months). Fas IHC failed in one tumor and p53 IHC in two. Fas immunoreactivity detected in 31/47 (67%) tumors assessed, was significantly associated with progression ($p=0.014$; $\chi^2$ test). Nuclear p53 IHC positivity was observed in 24/48 (50%) tumors and was significantly associated with progression, grade and stage ($p=0.046$, 0.014 and 0.021, respectively; $\chi^2$ test) (Fig. 2C).

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Target region</th>
<th>Primer name</th>
<th>5' Sequence 3'</th>
<th>PCR product (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSPCR</td>
<td>-548 CpG site</td>
<td>MF1C</td>
<td>GGTGTGTGTATTTAGGGATTTTGC</td>
<td>113</td>
</tr>
<tr>
<td>MSPCR</td>
<td>-548 CpG site</td>
<td>MR1C</td>
<td>CCAACCTCACTCCTTTCTAAAC</td>
<td>113</td>
</tr>
<tr>
<td>MSPCR</td>
<td>p53 enhancer</td>
<td>MF53</td>
<td>AGTTTCTGCCGTTTTTCCCGAGATTATTGC</td>
<td>184</td>
</tr>
<tr>
<td>MSPCR</td>
<td>p53 enhancer</td>
<td>UF53</td>
<td>GGTAGTTTTTGTTTTTTCGAGATTATTGT</td>
<td>187</td>
</tr>
<tr>
<td>MSPCR</td>
<td>Sp1 region</td>
<td>MFsp</td>
<td>GAGTTCGTGGTTTTTGC</td>
<td>131</td>
</tr>
<tr>
<td>MSPCR</td>
<td>Sp1 region</td>
<td>URsp</td>
<td>CACCCACACAAAAAACCTTTAAC</td>
<td>132</td>
</tr>
<tr>
<td>BGS</td>
<td>Fas promoter</td>
<td>PF</td>
<td>GGTGTGTGTATTTAGAGTTTTT</td>
<td>583</td>
</tr>
<tr>
<td>Mutation</td>
<td>Exon 9</td>
<td>AF</td>
<td>TGCTGGAGTGTAGTACACTAAT</td>
<td>175</td>
</tr>
<tr>
<td>Mutation</td>
<td>Exon 9</td>
<td>BF</td>
<td>TAAATTGGCATACACTTAC</td>
<td>191</td>
</tr>
<tr>
<td>Mutation</td>
<td>Exon 9</td>
<td>CR</td>
<td>CAATGTGTCATACGCTTCTTTC</td>
<td>156</td>
</tr>
</tbody>
</table>

Table I. Summary of the PCR primers used for mutational analysis, MSPCR and bisulphite genomic sequencing.
Fas immunoreactivity is most intense in T24 cells, but RT4 cells were the only cells to respond to Fas ligand and are most sensitive to MMC. Fas immunoreactivity was more intense and cytoplasmic (data not shown) in T24 cells (MCF=26.2) than in RT4 cells (MCF=7.6). T24 cells have mutated p53 and have been described as ‘mesenchymal’ cells with epithelial mesenchymal transition characteristics; RT4 cells have wt p53, are epithelial and less aggressive (23,24). Fas immunoreactivity was absent in HT1376 cells. The extra band detected by Western blotting in RT4 cells may represent a post-translational modification, such as glycosylation at the extracellular domain of the protein (25,26). RT4 cells were
Figure 3. RT4 cells are most MMC sensitive when compared to T24 and HT1376 bladder cancer cell lines. (A) Untreated cells were sequentially incubated with Fas, p53, IgG1 or IgG2b isotype antibodies, followed by red phycoerythrin labeled secondary antibody prior to analysis using quantitative flow cytometry. The isotype control histogram (not filled) was subtracted from the test histogram (filled) to determine the percentage of positively staining cells (% +ve) and the mean channel fluorescence (MCF). T24 cells exhibited intense Fas immunoreactivity in >95% of cells. (B) Membrane proteins (10 µg) extracted from HT1376, T24 and RT4 cell lines and probed for Fas again showed that Fas protein expression was greatest in T24 cells. (C) HT1376, RT4 and T24 cells were treated with 100, 200 or 500 µg/ml MMC for 1 h to mimic the clinical scenario and were then assessed for apoptosis after 24 h. The number of sub G0/G1 events was detected after propidium iodide staining. RT4 cells exhibited a classical dose response. T24 and HT1376 cells were resistant. (D) HT1376, T24 and RT4 cells were untreated or treated with between 1 and 200 µg/ml MMC. Fas protein expression was assessed using flow cytometry 24 h later. There was a classical dose response induction of Fas in RT4 cells. (E) Significant apoptosis was induced in RT4 cells following treatment with 100 ng/ml soluble recombinant human Fas-L for 16 h. (F) RT4 cells were treated with between 1 and 200 µg/ml MMC and harvested after 12 h for Western blot detection of nuclear p53 and after 24 h for detection of membranous Fas. After 12 h the band intensity for p53 increased as the MMC concentration increased and similarly, for Fas the band intensity increased after 24 h suggesting that Fas up-regulation might be p53-dependent.
Membranous Fas expression significantly increased in RT4 cells (p=0.002), but not in T24 (p=0.078) or HT1376 cells (p=0.229) 24 h after treatment with 1 µg/ml MMC. RT4 were the only cells responsive to Fas Ligand, suggesting that RT4 cells had functional Fas (Fig. 3).

**MMC response in RT4 cells is p53- and Fas-dependent.** Having established that levels of p53 increased prior to increases in Fas levels we wished to gain greater insight into the dynamics of p53 and Fas up-regulation in response to MMC using RT4 cells as a model. RT4 cells were originally derived from a grade 1 tumor expressing wt p53. To determine if Fas up-regulation was dependent on p53, RT4 cells were transfected with p53 siRNA before and after treatment. MMC-induced up-regulation of p53 and Fas in RT4 cells was significantly decreased following p53 siRNA (p<0.001). Furthermore, 24 h after treatment with 10 µg/ml MMC apoptosis was significantly less in RT4 cells transfected with FADD-DN than in mock transfected cells (p<0.001) (Fig. 4).

**Demethylation with 5-aza-2'deoxycytidine induced Fas immunoreactivity in HT1376 cells.** Having demonstrated that Fas plays an important role in the apoptotic response to MMC chemotherapy in RT4 cells, we investigated methylation as a possible mechanism of the Fas silencing observed in HT1376 cells. Treatment with 1 µM 5azadC for 72 h, significantly increased Fas immunoreactivity in RT4 cells, but did not change immunoreactivity in T24 cells or induce Fas immunoreactivity in HT1376 cells. However, 72 h after treatment with 12 µM 5azadC, Fas immunoreactivity increased in a sub-population of HT1376 cells and anti-SmMeC immunoreactivity was significantly reduced (p=0.010) (Fig. 5A-C).

**Methylation at a single CpG site in the Fas promoter: a novel methylation hotspot.** We investigated the methylation of specific CpGs in the promoter of Fas gene. Altered methylation may be responsible for the Fas immunoreactivity observed in HT1376 cells and the increased expression observed in RT4 after 5azadC treatment. We assessed the 28 CpG sites located within the Fas promoter (-575 to +8) using Bisulfite Genomic Sequencing (Table I). The Fas promoter region in HT1376, but not RT4 or T24 was methylated at a single CpG site (-548).

Methylation at this CpG (-548) in HT1376 was reversed following treatment with 12 µM 5azadC for 72 h (Fig. 5D).

Using MSPCR primers for CpG -548 in the Fas promoter (Table I) we detected methylated bands in 13/24 (54%) tumors assessed. Unexpectedly, eight of these tumors (62%) exhibited Fas immunoreactivity. Interestingly, this immunoreactivity was predominantly cytoplasmic. Possibly cytoplasmic Fas is non-functional. There was no association between methylation at CpG -548 and grade, stage or age. Patients with methylation had a mean age of 68.5 years compared to 66.3 years in those with unmethylated tumors. This was not statistically significant. When we assessed DNA extracted from 38 tumors, including six pT2 lesions, we found no evidence of methylation either within the p53 enhancer region of intron 1 or in the area adjacent to an SP-1 transcription factor binding site (Fig. 5E).

Similarly, we found no evidence of mutations in exon 9 of Fas as previously reported by Lee et al (20) (Fig. 6).

**Discussion**

A single CpG (-548) in the promoter of Fas was methylated in 13/24 (54%) bladder tumors that we investigated. This finding is important because we also report that demethylation of HT1376 cells induce Fas immunoreactivity. In addition, we highlight how functional Fas protein plays a key role in MMC-induced apoptosis and hence that its silencing may be associated with MMC resistance. We caution that Fas immunoreactivity is not, in itself, indicative of a good prognosis because in certain instances, similar to p53, it is not functional Fas. We are the first to report, in vivo, dynamic up-regulation of pro-apoptotic proteins, as detected by flow cytometry in tumor cells, and its associated with a favorable prognosis. These data together suggest that the ability of a tumor cell population to increase expression of pro-apoptotic proteins after MMC chemotherapy may predict response to MMC.

Because 16/48 bladder tumors did not express Fas, we investigated the mechanisms involved in Fas silencing. We identified a novel methylation hotspot at CpG site -548 within the Fas promoter and document, for the first time, an up-regulation and re-expression of membranous Fas in bladder cancer cells post-global demethylation in HT1376 cells. We monitored p53 protein expression post-5azadC treatment and found no evidence of increased p53 expression. This
confirms that increased Fas immunoreactivity was attributable to demethylation and not downstream effects of a p53 damage response to the demethylating agent (data not shown). The single CpG site which was hypermethylated in HT1376 cells has previously been reported in two colorectal cell lines (19). Our findings in HT1376 would suggest that there is a potential
methylating activity. Interestingly, T24 cells are known to be dependent on Bcl-2 for their resistance to MMC (30,31).

Possible mechanisms leading to aberrant Fas hypermethyl-lation in bladder cancer could be attributed to epigenetic dysregulation in the tumor microenvironment. Such environment-al factors include tumor hypoxia (32,33), DNA damage (34) and inflammation (35). Dysregulation in the enzymes that regulate DNA methylation may also be involved. The DNA methyltransferase 3b (Dnmt3b), which is responsible for generating de novo methylation during development, is dramatically overexpressed in several tumor cell lines and tumor specimens, including bladder (36,37). Kimura et al assessed 45 bladder tumors, 40 of which were high stage/grade, and reported that Dnmt3b mRNA levels were overexpressed in approximately half of the tumors examined, in comparison to levels in morphologically normal bladder tissues (38). One direct mechanism that results in Fas hypermethylation involves oncogenic Ras. Activating Ras mutations are extremely common in bladder tumors. Interestingly, T24 cells harbor the single point mutation at codon 12 present in >40% of bladder tumors (39-41). HT1376 cells have inactive Ras (42). Of significance, Ras has been implicated in the recruitment of DNA methyltransferases to the Fas gene promoter and the subsequent silencing of the Fas gene (43). These findings add to the evidence that the relationship between expression and hypermethylation in the promoter regions of genes in bladder cancer cells is complex as reported in the context of S100A4 (16).

We also investigated exon 9 mutations in the bladder tumors as a potential mechanism of Fas dysregulation. In contrast to Lee et al (20) who demonstrated 11 mutations in 42 patients with bladder cancer, we did not detect any exon 9 Fas mutations by direct sequencing. However, all but one of the patients Lee assessed had muscle invasive disease and 8 of the 11 mutations were an identical G→A transition at base pair position 993. Korkolopoulou et al (44) and Maas et al (6) who also studied bladder cancer were unable to replicate the findings of Lee et al (20). Explanation for the original finding by Lee et al may reflect the different ethnic population studied.

The impact of our study is that Fas plays a critical role in the response to MMC chemotherapy particularly in patients who present with superficial disease in the absence of p53 mutation, but in the presence of Fas promoter methylation. Unlike genetic alterations, epigenetic aberrations are reversible and thus provide interesting clinical relevance. Targeting bladder cancer patients harboring methylation at the single CpG site -548 within the Fas promoter site for treatment with demethylating drugs, such as Vidaza or Dacogen, could be employed as a single drug therapy or as a pre-sensitising strategy prior to MMC chemotherapy.

Acknowledgements

This study was supported by funding from Department of Employment and Learning Northern Ireland (DEL Research Award -18775993 to C.J.W., K.W. and P.M.); Royal Hospitals Trust [21278 (29632) Patrick Watt Memorial Trust Fund to K.W.]; British Urological Foundation [Edward Scott Memorial Scholarship (2004-2005) to H.O’K.], Belfast City Hospital Charitable Trust Funds (F/021-12/02 to H.O’K.), Peel Medical Research Trust (RRL.R10 to H.O’K.), Royal College of...
Surgeons Edinburgh (to H.O.K.); Research and Development Office Northern Ireland (EAT/1168/99 to J.McK.); Cancer Recognised Research Group Northern Ireland (to K.W. and J.McK.); Private donation in memory of GMJ [to C.J.W.]; Education and Culture Bureau, Egypt (MM172/N to O.S.) and by grants (KKK-05-05, NKFP_07_A2-MONODRUG, TECH_08_A2-STEMKILL, NAP_BIO_06-FLU_DRUG and OTKA-T046665 to I.P.). The authors acknowledge the kind gift of the FADD-DN construct from Vishva Dixit, Molecular Oncogeny, Genetec, San Francisco, CA, USA.

References


